M

Moleculin Biotech
D

MBRX

1.29000
USD
-0.15
(-10.42%)
مغلق
حجم التداول
23,450
الربح لكل سهم
-4
العائد الربحي
-
P/E
-0
حجم السوق
5,361,105
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    AGEN
    -0.11500
    (-3.34%)
    3.33000 USD
    A
    ALT
    -0.19000
    (-2.87%)
    6.42000 USD
    A
    APVO
    0.31000
    (9.48%)
    3.58000 USD
    A
    ASUR
    -0.150
    (-1.31%)
    11.260 USD
    B
    BNGO
    0.01500
    (0.28%)
    5.36500 USD
    C
    CYCC
    0.00240
    (0.70%)
    0.34610 USD
    E
    EVOK
    -0.21000
    (-4.02%)
    5.02000 USD
    O
    OCUL
    -0.26000
    (-3.58%)
    6.99500 USD
    P
    PGEN
    -0.07500
    (-3.81%)
    1.89500 USD
    T
    TNXP
    -0.53000
    (-5.48%)
    9.15000 USD
    المزيد
الأخبار
المقالات

العنوان: Moleculin Biotech

القطاع: Healthcare
الصناعة: Biotechnology
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.